Modulation of [3H]dopamine release from rat nucleus accumbens by neuropeptide Y may involve a Sigma1-like receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 2, 1998, Pages 553-560

  Ault, David T ^a   Radeff, Julie M ^a   Werling, Linda L ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; NEUROPEPTIDE Y; PENTAZOCINE; 1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; DRUG DERIVATIVE; N METHYLASPARTIC ACID; NEUROLEPTIC AGENT; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; PYX 1; SIGMA OPIATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; GUINEA PIG; LIGAND BINDING; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; ANIMAL; DRUG ANTAGONISM; IN VITRO STUDY; MALE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; MALE; N-METHYLASPARTATE; NEUROPEPTIDE Y; NUCLEUS ACCUMBENS; PENTAZOCINE; PEPTIDE FRAGMENTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031594393     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. 3H]dopamine release from rat striatum by neuropeptide Y and σ receptor ligands. Brain Res 760:210-217.
2. Bard JA, Walker MW, Branchek TA and Weinshank RL (1995) Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 270:26762-26765.
3. 2 binding sites in guinea pig hippocampus. J Pharmacol Exp Ther 267:961-970.
4. Bouchard P, DuMont Y, Fornier A, St.Pierre S and Quirion R (1993) Evidence for in vivo interactions between NPY-related peptides and σ receptors in the mouse hippocampal formation. J Neurosci 13:3926-3931.
5. Ceci A, Smith M and French ED (1988) Activation of the A10 mesolimbic system by the σ receptor agonist SKF10,047 can be blocked by rimcazole, a novel putative antipsychotic. Eur J Pharmacol 154:53-57.
6. Clissold DB, Pontecorvo MJ, Jones BE, Abreu ME, Karbon EW, Erickson RH, Natalie Jr KJ, Borosky S, Hartman T, Mansbach RS, Balster RL, Ferkany JW and Enna SJ (1993) NPC 16377, a potent and selective σ ligand. II. Behavioral and neuroprotective profile. J Pharmacol Exp Ther 265:876-886.
7. Cook L, Tam SW and Rohrbach KW (1992) DuP734 [1-(cyclopropylmethyl)-4-(2′(4″-fluorophenyl)-2′-oxoethyl) piperidine HBr], a potential antipsychotic agent: Preclinical behavioral effects. J Pharmacol Exp Ther 263:1159-1166.
8. 13-36 as selective Y1 and Y2 radioligands. J Pharmacol Exp Ther 272:673-680.
9. Dumont Y, Fournier A, St.-Pierre S, Schwartz TW and Quirion R (1990) Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. Eur J Pharmacol 191:501-503.
10. Dumont Y, Satoh H, Cadieux A, Taoudi-Benchekroun M, Pheng LH, St. Pierre S, Fournier A and Quirion R (1993) Evaluation of truncated neuropeptide Y modified in position 1 on various binding and bioassays. Eur J Pharmacol 238:37-45.
11. 34]Neuropeptide Y: A specific Y1 receptor agonist. Proc Natl Acad Sci USA 87:182-186.
12. Gehlert DR, Schober DA, Beavers L, Gadski R, Hoffman JA, Smiley DL, Chance RE, Lundell I and Larhammer D (1996) Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol Pharmacol 50:112-118.
13. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA and Weinshank RL (1996) A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382:168-171.
14. Goldstein SR, Matsumoto RR, Thompson TL, Patrick RL, Bowen WD and Walker JM (1989) Motor effects of two σ ligands mediated by nigrostriatal dopamine systems. Synapse 4:254-258.
15. 3H]DA release from rat striatal slices by σ receptor ligands. J Pharmacol Exp Ther 271:212-219.
16. Gregor P, Feng Y, DeCarr LB, Cornfield LJ and McCaleb ML (1996) Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J Biol Chem 271:27776-27781.
17. Grundemar L, Wahlestedt C and Reis DJ (1991) Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J Pharmacol Exp Ther 258:633-638.
18. 3H-hydroxylphenyl)-N-(1-propyl)-piperidine. J Neurosci 6:1757-1770.
19. 1-binding site. Proc Natl Acad Sci USA 93:8072-8077.
20. Higuchi H, Costa E and Yang H-YT (1988) Neuropeptide Y inhibits the nicotine-mediated release of catecholamines from bovine adrenal chromaffin cells. J Pharmacol Exp Ther 244:468-474.
21. Jewett DC, Cleary J, Levine AS, Schaal DW and Thompson T (1992) Effects of neuropeptide Y on food-reinforced behavior in satiated rats. Pharmacol Biochem Behav 42:207-212.
22. Jewett DC, Cleary J, Levine AS, Schaal DW and Thompson T (1995) Effects of neuropeptide Y, insulin, 2-deoxyglucose, and food deprivation on food-motivated behavior. Psychopharmacology Berl 120:267-271.
23. Josselyn SA and Beninger RJ (1993) Neuropeptide Y: Intraaccumbens injections produce a place preference that is blocked by cis-flupenthixol. Pharmacol Biochem Behav 46:543-552.
24. i protein to block the psychological stress and corticotropin releasing factor-induced colonic motor activation in rats. Neuropharmacology 30:1119-1124.
25. Leitner ML, Hohmann AG, Patrick SL and Walker JM (1994) Regional variation in the ratio of sigma1 to sigma2 binding in rat brain. Eur J Pharmacol 259:65-69.
26. Martin WR, Eades CG, Thompson JA, Huppler RE and Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532.
27. Mash DC and Zabetian CP (1992) Sigma receptors are associated with cortical limbic areas in the primate brain. Synapse 12:195-205.
28. Matsumoto M, Nomura T, Momose K, Ikeda Y, Kondou Y, Akiho H, Togami J, Kimura Y, Okada M and Yamaguchi T (1996) Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J Biol Chem 271:27217-27220.
29. McLean S and Weber E (1988) Autoradiographic visualization of haloperidol sensitive sigma receptors in guinea pig brain. Neuroscience 25:259-269.
30. Milligan G, Bond RA and Lee M (1995) Inverse agonism: Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16:10-13.
31. Monnet FP, Debonnel G, Fournier A and DeMontigny C (1992a) NPY potentiates the NMDA response in the CA3 hippocampus II. Involvement of a subtype of σ receptor. J Pharmacol Exp Ther 263:1219-1225.
32. 3H]-noradrenaline release in rat hippocampal slices. Brit J Pharmacol 119:65-72.
33. Monnet FP, Fournier A, Debonnel G, deMontigny C (1992b) NPY potentiates selectively the NMDA response in the rat CA3 dorsal hippocampus. I. Involvement of an atypical NPY receptor. J Pharmacol Exp Ther 263:1212-1218.
34. Pascaud XB, Chovet M, Roze C and Junien JL (1993) Neuropeptide Y and sigma receptor agonists act through a common pathway to stimulate duodenal alkaline secretion in rats. Eur J Pharmacol 2:389-394.
35. Peters J, Van Kammen DP, Gelernter J, Yao J and Shaw D (1990) Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophr Res 3:287-294.
36. Quirion R, Mount H, Chandieu I, Dumont Y and Boksa P (1991) Neuropeptide Y, polypeptide YY, phcncyclidine and sigma related agents: Any relationships? in NMDA and Related Agents: Biochemistry, Pharmacology and Behavior, (Kameyama T, Nebeshima T and Domino EF, eds) pp 203-210, NPP Books, Ann Arbor.
37. Riviere PJM, Rao RK, Pascaud X, Junien JL and Porreca F (1993) Effects of neuropeptide Y, peptide YY and sigma ligands on ion transport in mouse jejunum. J Pharmacol Exp Ther 264:1268-1274.
38. Roman FJ, Pascaud X, Duffy O, Vauche D, Martin B and Junien JL (1989) Neuropeptide Y and peptide YY interact with rat brain sigma and PCP binding sites. Eur J Pharmacol 174:301-302.
39. Salin P, Nieoullin A and Kerkerian-LeGoff L (1994) Reversal of the adaptive response of NPY neurons in the rat striatum to nigrostriatal dopamine deafferentiation by the NMDA antagonist dizocilpine maleate. Neuroscience 61:93-105.
40. Sather W, Dieudonne S, MacDonald JF and Ascher P (1992) Activation and desensitization of N-methyl-D-aspartate receptors in nucleated outside-out patches from mouse neurones. J Physiol 450:643-672.
41. Shibuya H, Mori H and Toru M (1992) Sigma receptors in schizophrenic cerebral cortices. Neurochem Res 17:983-990.
42. 3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618-5621.
43. Tam SW and Mitchell KN (1991) Neuropeptide Y and peptide YY do not bind to brain sigma and phencyclidine receptors. Eur J Pharmacol 193:121-122.
44. Tam SW, Steinfels GF, Gilligan PJ, Schmidt EK and Cook L (1992) DuP734, a potential antipsychotic agent: Preclinical behavioral effects. J Pharmacol Exp Ther 263:1167-1174.
45. Tam SW and Zhang A-Z (1988) Sigma and PCP receptors in human frontal cortex membranes. Eur J Pharmacol 154:343-344.
46. Tatemoto K, Mann MJ and Shimizu M (1992) Synthesis of receptor antagonists of neuropeptide Y. Proc Natl Acad Sci USA 89:1174-1178.
47. Vaupal DB (1982) Naltrexone fails to antagonize the sigma effects of PCP and SKF10,047 in the dog. Eur J Pharmacol 92:269-274.
48. Vilner BJ and Bowen WD (1992) Characterization of sigma-like binding sites of NB41A3, S-20Y and N1E-115 neuroblastomas, C6 glioma, and NG108-15 neuroblastoma-glioma hybrid cells. in Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection, (Kamenka JM and Domino EF, eds) pp 341-353, NPP Books, Ann Arbor.
49. Vilner BJ, deCosta BR and Bowen WD (1995) Cytotoxic effects of sigma ligands; Sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15:117-134.
50. Wahlestedt C, Grundemar L, Hakanson R, Heilig M, Shen GH, Zukowaka-Grojec Z and Reis DJ (1990) Neuropeptide Y receptor subtypes, Y1 and Y2. in Central and Peripheral Significance of Neuropeptide Y and Its Related Peptides, Vol. 611, (Allen JM and Koenig JI, eds) pp 7-26, New York Acad Sci, NY.
51. Wahlestedt C, Regunathan S and Reis DJ (1992) Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life Sci 50:PL-7-PL-12.
52. Wahlestedt C and Reis DJ (1993) Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol 32:309-352.
53. Walker JM, Bowen WD, Walker FO, Matsumoto RR, deCosta B and Rice KC (1990) Sigma receptors: Biology and function. Pharm Rev 42:355-402.
54. 3H]dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophrenia Res 21:51-62.
55. Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader CD, Linemeyer DL and MacNeil DJ (1996) Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 271:16435-16438.
56. Weissman AD, Casanova MF, Kleinman JE, London ED and De Souza EB (1991) Selective loss of cerebral cortical sigma, but not PCP, binding sites in schizophrenia. Biol Psychiatry 29:41-54.
57. Weissman AD, Su TP, Hedreen JC and London ED (1988) Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 247:29-33.
58. Werling LL, Frattali A, Portoghese PS, Takemori AE and Cox BM (1988) Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J Pharmacol Exp Ther 246:282-286.
59. 2 receptor subtypes in human and rat brain. Brain Res 631:27-38.
60. Zilberter Y, Uteshev V, Sokolova S and Khodorov B (1991) Desensitization of N-methyl-D-aspartate receptors in neurons dissociated from adult rat hippocampus. Mol Pharmacol 40:337-341.